ERBB2 and breast cancer: Interestingly, Loi’s group through analyzing 44 publicly available microarray datasets about 6,209 breast cancer samples, they implied CD73 gene expression was associated with worse prognosis in triple negative breast cancer patients (HR = 1.5, 95% CI = 1–2.1, p = 0.029), but not in Luminal type (HR = 0.96, 95% CI = 0.77–1.2, p = 0.7) or HER2 positive type(HR = 1.0, 95% CI = 0.71–1.5, p = 0.86) [2].